Commentary: Hormone therapy and breast cancer incidence: Did epidemiologists miss an effect on national trends?

International Journal of Epidemiology

Volumn 37, Issue 3, 2008, Pages 638-640

  Paul, Charlotte ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GESTAGEN;

AGE DISTRIBUTION; BREAST CANCER; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER RISK; CANCER SCREENING; DRUG EFFICACY; DRUG MEGADOSE; EARLY DIAGNOSIS; EVIDENCE BASED MEDICINE; HUMAN; MAMMOGRAPHY; NOTE; PRIORITY JOURNAL; TREND STUDY;

BREAST NEOPLASMS; DATA INTERPRETATION, STATISTICAL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; INCIDENCE; MIDDLE AGED; RISK; TIME; WORLD HEALTH;

EID: 44949105232     PISSN: 03005771     EISSN: 14643685     Source Type: Journal    
DOI: 10.1093/ije/dyn058     Document Type: Note

References (18)

1. Petitti D. Commentary: Hormone replacement therapy and coronary heart disease: Four lessons. Int J Epidemiol 2004;33:461-63.
2. Krieger N, Lowy I, Aronowitz R et al. Hormone replacement therapy, cancer, controversies, and women's health: Historial, epidemiological, clinical, and advocacy perspectives. J Epidemiol Community Health 2005;59:740-48.
3. Krieger N. Hormone therapy and the rise and perhaps fall of US breast cancer incidence rates: Critical reflections. Int J Epidemiol 2008;37:627-37.
4. Clegg LX, Feuer EJ, Midthune DN, Fay MP, Hankey BF. Impact of reporting delay and reporting error on cancer incidence rates and trends. J Natl Cancer Inst 2002;94: 1537-45.
5. Armstrong B. Oestrogen therapy after the menopause - boon or bane? Med J Aus 1988;148:213-14.
6. Dupont WD, Page DL. Menopausal estrogen replacement therapy and breast cancer. Arch Intern Med 1991;151: 67-72.
7. Steinberg KK, Thacker SB, Smith SJ et al. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA 1991;265:1985-90.
8. Rosenberg L. Hormone replacement therapy: The need for reconsideration. Am J Public Health 1993;83:1670-73.
9. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52705 women with breast cancer and 108411 women without breast cancer. Lancet 1997;350:1047-59.
10. Kennedy DL, Baum C, Forbes MB. Non-contraceptive estrogens and progestins: Use patterns over time. Obstet Gynecol 1985;65 441-46.
11. Lawson DH, Jick H, Hunter JR, Madsen S. Exogenous estrogens and breast cancer. Am J Epidemiol 1981;114: 710-13.
12. Hemminki E, Kennedy DL, Baum C, McKinlay SM. Prescribing of noncontraceptive estrogens and progestins in the United States, 1974-86. Am J Public Health 1988; 78:1478-81.
13. Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy: Annual trends and response to recent evidence. JAMA 2004;291:47-53.
14. Bergkvist L, Adami H-O, Persson I, Hoover R, Schairer C. The risk of breast cancer after estrogen and estrogen-progestin replacement. N Engl J Med 1989;321:293-97.
15. Colditz GA. Estrogen, Estrogen plus progestin therapy, and risks of breast cancer. Clin Cancer Res 2005; 11(Suppl):909S-17S.
16. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-27.
17. Rossouw JE, Anderson GL, Prentice RL et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
18. Anderson GL, Limacher M, Assaf AR et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative randomized controlled trial. JAMA 2004;291 1701-12.